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A B S T R A C T
Purpose
We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP),
and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosar-
coma of the extremity.
Patients and Methods
Patients age  40 years randomly received regimens with the same cumulative doses of drugs
(ADM 420 mg/m2, MTX 120 g/m2, CDP 600 mg/m2, and IFO 30 g/m2) but with different durations
(arm A, 44 weeks; arm B, 34 weeks). IFO was given postoperatively when pathologic response to
MTX-CDP-ADM was poor (arm A) or given in the primary phase of chemotherapy with MTX-CDP-
ADM (arm B). End points of the study included pathologic response to preoperative chemother-
apy, toxicity, and survival. Given the feasibility of accrual, the statistical plan only permitted
detection of a 15% difference in 5-year overall survival (OS).
Results
From April 2001 to December 2006, 246 patients were enrolled. Two hundred thirty patients
(94%) underwent limb salvage surgery (arm A, 92%; arm B, 96%; P .5). Chemotherapy-induced
necrosis was good in 45% of patients (48% in arm A, 42% in arm B; P  .3). Four patients died
of treatment-related toxicity (arm A, n  1; arm B, n  3). A significantly higher incidence of
hematologic toxicity was reported in arm B. With a median follow-up of 66 months (range, 1 to 104
months), 5-year OS and event-free survival (EFS) rates were not significantly different between
arm A and arm B, with OS being 73% (95% CI, 65% to 81%) in arm A and 74% (95% CI, 66%
to 82%) in arm B and EFS being 64% (95% CI, 56% to 73%) in arm A and 55% (95% CI, 46% to
64%) in arm B.
Conclusion
IFO added to MTX, CDP, and ADM from the preoperative phase does not improve the good
responder rate and increases hematologic toxicity. IFO should only be considered in patients who
have a poor histologic response to MTX, CDP, and ADM.
J Clin Oncol 30:2112-2118. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Probability of survival in patients with nonmeta-
static osteosarcoma of the extremity has improved
dramatically with the addition of chemotherapy
tosurgicalremovalofthetumor.1Multiagentchem-
otherapy has been used since the 1970s, but a
standard chemotherapy regimen has not yet
been defined.2
A previous clinical trial conducted by the Ital-
ianSarcomaGroup(ISG)andtheScandinavianSar-
coma Group (SSG), ISG/SSG-1, used the following
four active drugs against osteosarcoma: methotrex-
ate (MTX), cisplatin (CDP), doxorubicin (ADM),
and ifosfamide (IFO).3 ISG/SSG-1 involved an in-
tensified chemotherapy treatment that included
IFO delivered at a high dose (3 g/m2 per day over a
5-day continuous infusion).3 Results of the study
showed that addition of high-dose IFO to MTX,
CDP, andADMwas feasible, but survival rates were
similar to those obtained with less intensive four-
drug regimens using standard-dose IFO.3
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A new study (ISG/OS-1) was subsequently designed by the ISG
with the aim of optimizing the drug administration schedule. Two
different chemotherapy regimens were compared, both based on the
four active drugs given according to different schemes, but with the
same cumulative doses. Protocols differed in terms of dose-intensity
and modality of use of IFO. Final results of the ISG/OS-1 study are
reported here.
PATIENTS AND METHODS
Study Design
ISG/OS-1 was a multicenter randomized trial comparing efficacy and
toxicity of twochemotherapy regimens, bothbasedonMTX,CDP,ADM,and
IFO and with the same cumulative doses but administered according to dif-
ferent schemes. The protocols had a different dose-intensity and different
modality of use of IFO. In arm A, IFO was given only postoperatively and in
patients with poor histologic response to primary chemotherapy with MTX,
CDP, andADM. In armB, IFOwasdelivered in all patients and in the primary
phase of chemotherapy.
Random Assignment
The IstitutoOrtopedicoRizzoli EthicCommittee secretariatwas respon-
sible for the random assignment procedures. For allocation of the participant
patients, a computer-generated list of random numbers was used. Eligible
patients were randomly assigned by fax to arm A or B.
Patient Selection
Eligibility criteria for entry onto the study were diagnosis of primary,
central, high-gradeosteosarcomaof the extremity; age40 years; andnormal
hepatic, renal, bone marrow, and cardiac function. The local ethics commit-
tees approved the protocol. After explanation of the research study and of the
related procedures, a written informed consent was obtained from the adult
patients or from legally authorized representatives if the patients wereminors.
Representative histologic slides and radiographic images were cen-
trally reviewed. Exclusion criteria were as follows: evidence of overt meta-
static disease at diagnosis, previous treatment for osteosarcoma, medical
contraindications to the drugs included in the protocol, and lack of avail-
ability for follow-up.
The primary tumor was evaluated on plain radiographs, computed to-
mography (CT) scans, and/or magnetic resonance imaging scans. Screening
formetastaseswasbybone scintigraphyandCTscanningof the chest. Baseline
studies included CBC, serum electrolytes, and glomerular filtration rate esti-
mation; serum alkaline phosphatase and lactate dehydrogenase levels; biliru-
bin and aminotransferase levels; and echocardiography.
Treatment Plan and Follow-Up
Eligible patients underwent primary chemotherapy. Before surgery, CT
and/or magnetic resonance imaging of the tumor and CT of the chest were
repeated. After surgery, surgicalmargins were assessed according to Enneking
et al,4 and histologic analysis of the tumormap was performed in accordance
with a method reported previously.5 When the percentage of tumor necrosis
was  90%, patients were classified as good responders (GRs); when the
percentage of tumor necrosis was lower, patients were defined poor respond-
ers (PRs).Diagnosis,histologic subtype, andhistologic responsewere reviewed
byanexpertpanelofpathologists.After completionof chemotherapy,patients
were observed by x-ray of the operated limb and CT scan of the chest every 3
months for 2 years, at 4-month intervals during the third and fourth years, and
subsequently every 6months.
Chemotherapy
TheCONSORTdiagramis inFigure1, andthechemotherapyprotocol is
outlined in Figure 2. Cumulative doses (MTX 120 g/m2, CDP 600 mg/m2,
ADM 420 mg/m2, and IFO 30 g/m2) were the same in the two arms. The
plannedoveralldurationof treatmentwas43weeks forarmA(34weeks incase
of goodhistologic response) and34weeks for armB.Details on chemotherapy
administration are listed in Appendix Table A1 (online only).
Statistics
A total of 246 patientswas required to detect a survival difference of 15%
or higher at 5 years between the two groups (study power of 80%, type I error
of 5%). With an expected enrollment rate of 45 to 50 patients per year, the
recruitment period was set at 5 years.
The two armswere compared in terms of protocol compliance, toxicity,
and survival. Compliancewith theprotocolwas evaluated for eachpatient and
was expressed in terms of relative received dose of each drug (cumulative
received dose to cumulative protocol-planned dose [in milligrams per square
meter] ratio). Furthermore, for each patient, the received dose-intensity
(RD/I) was calculated by dividing the average of relative received cumulative
doses by the relative chemotherapy duration (ratio between actual duration of
chemotherapy treatment and protocol-planned duration). The t test was used
for comparing protocol compliance between the two regimens.
Toxicity was graded according to the National Cancer Institute Com-
monToxicityCriteria (version 2.0). Toxicitywas assessed by comparing grade
4WBCandplatelet toxicity, febrile neutropenia andhospitalization rate, RBC
and PLT transfusions, and granulocyte colony-stimulating factors (G-CSF)
requirement using Fisher’s exact test.
Event-free survival (EFS)was calculated fromthefirst dayof chemother-
apy to recurrence (local or distant), death from all causes, the appearance of
secondary tumors, or the last follow-up examination. Overall survival (OS)
was calculated from the first day of chemotherapy to death or the last
follow-up examination. Survival curves in the two arms and according to the
clinical characteristics and chemotherapy-related variables were calculated
using the Kaplan-Meier method and compared using the log-rank test.
RESULTS
The ISG/OS-1 protocol was activated in April 2001 and closed in
December 2006. Two hundred forty-six patients whomet the eligibil-
ity criteria were randomly assigned (Fig 1). Clinical characteristics
were well balanced between the two arms (Table 1).
Treatment Compliance
Case report formswere incomplete for 15patients (6%).Anearly
progression was documented in eight patients during the primary
phase. For the remaining 223 patients, the ratio between real and
planned duration of the chemotherapy treatment was 1.1  0.3 for
patients in armAand 1.24 0.3 for patients in armB (P .005). The
median RD/I of the protocol was 0.82. The RD/I was 0.92 0.03 for
patients in arm A and 0.74 0.05 for patients in arm B (P .02).
Toxicity
Four patients died of causes unrelated to the disease. Two boys,
age 11 (arm A) and 14 (arm B) years old, developed an acute, fatal
cardiomyopathy. The first patient developed acute cardiomyopathy
during an episode of febrile neutropenia after the last CDP cycle. The
second patient developed acute cardiomyopathy during the last ad-
ministration of MTX. Both patients received the cumulative dose of
ADM of 420 mg/m2. The echocardiograms performed before ADM
administration were in a normal range.
One patient (armB) died of a disseminated intravascular coagu-
lation that complicated a sepsis possibly related to a surgical infection.
One patient (arm B) died of Stevens-Johnson syndrome that arose
during an episode of febrile neutropenia.
After high-dose MTX, one patient (arm B) experienced acute
renal failure that required a transient dialysis treatment. He is pres-
ently alive withmild renal impairment. In seven patients (armA, n
3; arm B, n  4), mild to moderate renal toxicity was reported that
Randomized Trial of Chemotherapy for Nonmetastatic Osteosarcoma
www.jco.org © 2012 by American Society of Clinical Oncology 2113
Downloaded from ascopubs.org by Universita Studi Di Torino on April 9, 2020 from 130.192.119.093
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
caused changes in the planned treatment schedule and no additional
administration of nephrotoxic drugs. Four patients are presently alive
with renal function in a normal range.
Besides the two deaths already reported, in 11 patients (arm A,
n7; armB,n4), a reductionofejection fractionofmore than10%
comparedwith the baseline value was observed. In four patients (arm
A, n  3; arm B, n  1), the reduction of the ejection fraction was
associated with clinical evidence of cardiomyopathy. These four pa-
tients are all presently alive and under cardiologic treatment.
In 1,553 cycles of MTX evaluated, the incidence of delayed
excretion was 7.6% in arm A and 8.2% in arm B. In only four
patients (arm A, n 2; arm B, n 2), delayed excretion of MTX
was associated with persistent renal impairment (in one patient,
transient dialysis was required).
Data on hematologic toxicities are listed in Table 2. Patients
treated in armBhad a significantly higher incidence of grade 4 leuko-
penia and thrombocytopenia andmore frequently experienced febrile
neutropenia requiring more frequent hospitalization, RBC and or
platelet transfusions, and the use of G-CSF. A higher incidence of
hematologic toxicitywas alsoobserved in armBwhen the analysiswas
restricted to patients in arm A who received all four drugs (data
not shown).
Surgery and Histologic Response
Two patients, one in arm A and one in arm B, did not undergo
surgery because of an early systemic progression of the disease. Of the
remaining 244 patients, 230 (94%) underwent conservative surgery,
12 (5%) underwent amputation, and two (1%) underwent rotation-
plasty. Surgicalmargins, reported in 215patients,were adequate (rad-
ical or wide) in 204 patients (95%) andmarginal in 11 patients (5%).
No differences were observed between the two arms (Appendix Table
A2, online only).
Chemotherapy-induced tumor necrosis was rated as good in
45%ofpatients (110of 244patients).TheGRratewas 48%inpatients
treated inarmAand42%inpatients treated inarmB(P .3).TheGR
rate did not differ according to sex and age but was lower in chondro-
blastic subtype (Appendix Table A3, online only).
Follow-Up
A total of 176 patients (71.5%) were alive with a median
follow-up time of 76 months (range, 31 to 115 months), and the
5-year probability of OS was 74% (95%CI, 68% to 79%). Patients in
arm A had a 5-year OS of 73% (95% CI, 65% to 81%), whereas
patients treated in arm B had a 5-year OS of 74% (95% CI, 66% to
82%; P .6; Fig 3).
One hundred forty-four patients (58.5%) were continuously
event free. Tumor progression (local or distant) was reported in 95
patients (39%), four patients died of toxicity, and three patients expe-
rienced a secondmalignant neoplasm (acute lymphoblastic leukemia
in twopatients and colon cancer in one patient). Local recurrencewas
reported in 18 patients (in five patients, combined withmetastasis).
Assessed for eligibility 
(N = 337)
Randomly assigned
(n = 246)
Arm A
(n = 123)
Arm B
(n = 123)
Excluded
   Not meeting inclusion 
      criteria
         Age
         Histology
         Stage
   Declined to participate
Early progression of disease 
   during primary chemotherapy
Did not undergo surgery
Toxic death
   Fatal cardiopathy
(n = 4)
(n = 1)
(n = 1)
(n = 1)
Analyzed for EFS and OS (n = 123)
Analyzed for EFS and OS (n = 123)
Early progression of disease 
   during primary chemotherapy
Did not undergo surgery
Toxic death
   Disseminated intravascular 
      coagulation
   Stevens-Johnsons syndrome
   Fatal cardiopathy
(n = 4)
(n = 1)
(n = 3)
(n = 1)
(n = 1)
(n = 1)
(n = 91)
(n = 80)
(n = 22)
(n = 14)
(n = 44)
(n = 11)
Fig 1. CONSORT diagram. EFS, event-
free survival; OS, overall survival.
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The 5-year probability of EFS was 60% (95% CI, 53% to 66%).
Patients in arm A had a 5-year EFS of 64% (95% CI, 56% to 73%),
whereas patients treated in arm B had a 5-year EFS of 55% (95% CI,
46% to 64%; P .2; Fig 3).
EFS was lower when alkaline phosphatase and lactate dehydro-
genase (LDH) were elevated, whereas EFS did not differ according to
sex, tumor site, and histologic subtype (Table 3). GR patients had a
significantly better probability of EFS compared with PR patients
(Table 4). Five-year EFSwas 69% (95%CI, 60% to 78%) for GRs and
52% (95% CI, 44% to 61%) for PRs (log-rank P  .001). Protocol
compliance had no impact on EFS (Table 4). Multivariate analyses
(via Cox regression) were performed. LDH (high LDH: relative risk,
1.9; 95% CI, 1.17 to 3.1; P  .009) and histologic response (GR:
relative risk, 0.6; 95% CI, 0.38 to 0.98; P .04) independently influ-
enced EFS.
DISCUSSION
In patients with high-grade osteosarcoma, chemotherapy was first
used in the early 1970s.6 Since then, several schemes of multiagent
chemotherapy have been assessed, but at present, there is no agree-
ment on a standard chemotherapy regimen.2
Inour study,wecompared twodifferent chemotherapyregimens
basedon the four activedrugs against osteosarcoma, and inparticular,
we focused on the role of IFO. The drugwas used only in case of poor
histologic response to the MTX-CDP-ADM regimen (arm A) or was
added to MTX-CDP-ADM in all patients in the primary phase of
chemotherapy (arm B).
The two regimens had a significantly different hematologic
toxicity. Patients treated in arm B were more frequently hospital-
ized because of a higher incidence of neutropenic fever and need of
transfusion support. More frequently, patients in arm B required
the use of G-CSF. The fact that approximately 50% of patients
treated in arm A did not receive IFO is an important factor but is
not the only factor that might explain the different hematologic
toxicity. It is important to highlight that, when comparison ismade
considering only patients in arm Awho received IFO, hematologic
toxicity still remains significantly higher in arm B. This fact clearly
indicates the importance of the administration modality of the
drugs and the direct relation between dose-intensity of treatment
and hematologic toxicity, which, in our study, was not compen-
sated by a higher use of G-CSF. Toxicity observed in arm B had a
direct influence on protocol compliance, which was lower than the
compliance reported for arm A.
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Fig 2. Protocol outline for arm A (A) preoperative chemotherapy and (B) postoperative chemotherapy, using methotrexate (M) 12 mg/m2, cisplatin (P) 120 mg/m2,
doxorubicin (A, adriamycin) 75 mg/m2, and ifosfamide (I) 10 g/m2, and arm B (C) preoperative chemotherapy and (D) postoperative chemotherapy, using M 12 g/m2,
P 120 mg/m2, A 70 mg/m2, and I 6 g/m2. GR, good histologic response; PR, poor histologic response.
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Abetter protocol compliance did not translate to better survival.
This is in agreementwith theEuropeanOsteosarcoma Intergroupand
Cooperative Osteosarcoma Study Group experiences regarding the
absence of impact on survival of the RD/I in patients with nonmeta-
static osteosarcoma.7,8
A similar probability of survival was obtained in the two arms.
Onthebasisof the resultsof the ISG/OS-1 study, armAispresently the
chemotherapy treatment recommended by the ISG for patients with
nonmetastatic osteosarcoma of the extremity outside of clinical trials.
These data are in agreement with those reported in previous
studies in which the four drugs had been used.3,9-12 A slightly higher
probability of survival was reported only in one of the four randomly
assigned arms of the last INT-0133 study.13 Patients treated with
MTX-CDP-ADM plus IFO with the addition of the immunostimu-
lating agent mifamurtide achieved a 6-year probability of survival of
81%. In accordance with previous publications,14,15 a good histologic
response was predictive of survival in ISG/OS-1.
Our study provides additional information on pathologic re-
sponse in osteosarcoma because of the possibility of comparing two
Table 2. Hematologic Toxicity by Random Assignment Arm (doxorubicin, ifosfamide, and cisplatin cycles)
Toxicity
Per Cycle
P
Per Patient
P
Arm A
(n  865 cycles)
Arm B
(n  823 cycles)
Arm A
(n  123 patients)
Arm B
(n  123 patients)
No. % No. % No. % No. %
Grade 4 leukopenia 260 30 568 69  .001 79 64 117 95  .001
Grade 4 thrombocytopenia 112 13 329 40  .001 60 49 103 84  .001
RBC transfusion 104 12 280 34  .001 43 35 96 78  .001
PLT transfusion 52 6 214 26  .001 31 25 79 64  .001
G-CSF 554 64 593 72  .002 103 84 123 100  .001
Neutropenic fever 138 16 206 25  .002 52 42 87 71  .001
Hospitalization 61 7 165 20  .001 54 44 93 76  .001
Abbreviations: G-CSF, granulocyte colony-stimulating factor; PLT, platelet.
Table 1. Demographics and Clinical Characteristics by Random
Assignment Arm
Demographic or Clinical
Characteristic
All Patients
Patients in
Arm A
Patients in
Arm B
PNo. % No. % No. %
Total patients 246 123 50 123 50
Age, years
Median 14 4-39 14 6-39 14 4-34
Range
Sex .8
Male 146 59 74 60 72 59
Female 100 41 49 40 51 41
Site .3
Femur 131 53 62 50 69 56
Tibia 60 25 34 28 26 21
Humerus 34 14 14 11 20 16
Other 21 8 13 11 8 7
SAP (n  209) .3
Normal 125 60 65 62.5 60 57
High 84 40 39 37.5 45 43
LDH (n  198) .2
Normal 136 69 72 72 64 65
High 62 31 28 28 34 35
Histology .5
Osteoblastic 157 64 76 62 81 66
Chondroblastic 24 10 12 10 12 10
Fibroblastic 23 9 11 9 12 10
Telangiectatic 23 9 15 12 8 6
NOS 19 8 9 8 10 8
Abbreviations: LDH, lactate dehydrogenase; NOS, high-grade osteosarcoma
not otherwise specified; SAP, serum alkaline phosphatase.
A
0
Ev
en
t-F
re
e 
Su
rv
iv
al
 
(p
ro
ba
bi
lit
y)
Time From Diagnosis (months)
1.0
0.8
0.6
0.4
0.2
20 40 60 80
Arm A
Arm B
100 120
B
0
Ov
er
al
l S
ur
vi
va
l 
(p
ro
ba
bi
lit
y)
Time From Diagnosis (months)
1.0
0.8
0.6
0.4
0.2
20 40 60 80 100 120
Arm A
Arm B
Fig 3. Probability of (A) event-free survival and (B) overall survival by random
assignment arm.
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different schemes of primary chemotherapy. No differences were ob-
served between the two arms, and the addition of IFO toMTX-CDP-
ADM did not influence the rate of GR. The two arms were well
balanced in terms of factors influencing histologic response such as
age and histologic subtypes.16,17 The percentage of patients who un-
derwent conservative surgery was 94%; the more intensive four-drug
primary treatment did not allow a higher resection rate compared
with theMTX-CDP-ADMregimen.Thesedatadonot support theuse
of IFO added toMTX-CDP-ADM in primary chemotherapy of non-
metastatic osteosarcoma of the extremity, at least with the dose and
schedule used in our study.
A strategy based on an interval compression in patients with
osteosarcomahasbeenassessedby theEuropeanOsteosarcoma Inter-
group.18 The authors reported that intensification of chemotherapy
increasedRD/I and resulted in an increased response rate, but this did
not translate into a better survival comparedwith the standard chem-
otherapy arm. These results do not support an interval compression
in osteosarcoma.
Results of the present study allow a better understanding of the
role of IFO in patients with nonmetastatic high-grade osteosarcoma.
Its use in the primary phase added toMTX-CDP-ADM is not recom-
mended, and it is associated with greater hematologic toxicity.
Similar conclusionsmight be drawn from the results of the INT-
0133 study.13 In the Children’s Cancer Group–Pediatric Oncology
Group study, patients treated with MTX-CDP-ADM, without the
addition of mifamurtide, had a better 6-year EFS (64%) compared
Table 3. Probability of Survival by Clinical Characteristics
Characteristic No. of Patients
EFS OS
5-Year EFS (%) 95% CI (%) Log-Rank P 5-Year OS (%) 95% CI (%) Log-Rank P
Sex
Male 146 68 59 to 78 .15 71 63 to 79 .16
Female 100 65 55 to 74 79 70 to 88
Age, years
3-10 42 78 66 to 91 .07 82 70 to 94 .3
11-17 131 58 50 to 67 76 69 to 84
 17 73 54 42 to 66 65 51 to 78
SAP 209
High 84 54 43 to 65 .02 66 57 to 77 .06
Normal 125 68 59 to 76 80 73 to 88
LDH 198
High 62 50 37 to 63 .02 70 58 to 81 .2
Normal 136 65 57 to 73 75 68 to 83
Histology
Osteoblastic 157 60 52 to 68 .13 72 65 to 80 .2
Chondroblastic 24 53 31 to 74 71 49 to 93
Fibroblastic 23 71 51 to 90 89 75 to 100
Telangiectatic 23 78 61 to 95 86 72 to 100
NOS 19 38 12 to 63 58 31 to 85
Abbreviations: EFS, event-free survival; LDH, lactate dehydrogenase; NOS, high-grade osteosarcoma not otherwise specified; OS, overall survival; SAP, serum
alkaline phosphatase.
Table 4. Probability of Survival by Chemotherapy-Related Variables
Variable No. of Patients
EFS OS
5-Year EFS (%) 95% CI (%) Log-Rank P 5-Year OS (%) 95% CI (%) Log-Rank P
RD/I 223
 80% 110 65 54 to 75 .3 77 67 to 86 .6
 80% 113 58 47 to 68 76 66 to 85
Tumor necrosis in all patients 244
GR 110 69 60 to 78 .001 82 75 to 90 .01
PR 134 52 44 to 61 70 61 to 78
Tumor necrosis in arm A
GR 59 76 65 to 88 .02 83 72 to 93 .09
PR 63 56 43 to 69 70 57 to 82
Tumor necrosis in arm B
GR 51 65 52 to 78 .2 81 70 to 93 .1
PR 71 51 39 to 64 69 58 to 81
Abbreviations: EFS, event-free survival; GR, good responder (tumor necrosis  90%); OS, overall survival; PR, poor responder (tumor necrosis  90%); RD/I,
received dose-intensity.
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with patients treated with the four-drug combination (MTX-CDP-
ADM-IFO), whohad a 6-year EFS of 58%.The probability of survival
at 6 years was 71% with the three-drug regimen and 70% with the
four-drug regimen. It is interesting to observe that despite the differ-
ences in termsof cumulativedose and schedulebetween theAmerican
studyandourstudy, survival results are similar.This fact reinforces the
doubt that IFO is needed in first-line chemotherapy in patients with
nonmetastatic osteosarcoma of the extremity.
In the interpretation of the results of our study, some limitations
havetobeconsidered.Thesamplesizewascalculatedtodetectadifference
insurvivalbetweenthetwoarmsof15%ormore.Inaddition,onthebasis
of previous clinical trials of adjuvant chemotherapy, this percentagemay
be considered high. This choice was determined by the expected annual
enrollment rate of eligible patients by the ISG.
In arm A, IFO was given only in patients with poor response to
MTX-CDP-ADM in an attempt to improve their survival. The chem-
otherapy scheme of arm A was based on a previous protocol (IOR/
OS-2) in which IFO was used only in PRs to primary chemotherapy
withMTX-CDP-ADM. In that study,we reported a difference of 11%
in termsofEFSbetweenGRs andPRswho receivedpostoperative IFO
(5-year EFS: GR, 67%; PR, 56%).19
In ISG/OS-1, EFS probability was higher in GR patients com-
pared with PR patients who also received IFO. The study was not
designed to explore IFO as salvage chemotherapy in PR patients, and
no conclusions in this direction can be drawn.Wemust keep inmind
that a recent SSG report13 failed to show an advantage when IFO
added toMTX-CDP-ADMwas used in PR patients. In the Scandina-
vian study, the dose of IFOwas similar to that adopted in our study. It
is possible that ahigherdoseor adifferent schedulemightbebeneficial
in PR patients. A more definitive conclusion could probably come
from the results of the EURAMOS-1 study20 where patients who are
PRs to MTX-CDP-ADM are randomly assigned to receive or not to
receive IFO and etoposide.
The addition of IFO toMTX, CDP, and ADM in the preoperative
phase does not improve the rate of patients with a good histologic re-
sponseandincreaseshematologic toxicity. IFOshouldonlybeconsidered
inpatientswhohaveapoorhistologicresponsetoMTX,CDP,andADM.
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